SH2D5 promotes lung adenocarcinoma cell metastasis and triggers EMT via activating AKT signaling pathway
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0316432 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Licheng Du und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology, College of Chemistry & Life Science, Beijing University of Technology, Chaoyang, Beijing, China. Hauptthemen laut MEDLINE: Epithelial-Mesenchymal Transition, Proto-Oncogene Proteins c-akt, Adenocarcinoma of Lung, Lung Neoplasms. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Lung adenocarcinoma (LUAD) is the most common histological subtype of lung cancer, characterized by a high incidence in late stages, high mortality rate, and poor prognosis. Src Homology 2 Domain Containing Protein 5 (SH2D5) is a mammalian-specific, uncharacterized scaffolding protein, and its role in LUAD remains unclear. In the present study, we investigated the function and potential mechanisms of SH2D5 in the progression of LUAD. We found aberrant expression of SH2D5 in LUAD tissues and cells, and its high expression is closely associated with poor prognosis in LUAD patients. Through loss-of-function and gain-of-function experiments, we revealed that overexpression of SH2D5 promotes the proliferation and migration abilities of lung adenocarcinoma cells. Gene set enrichment analysis (GSEA) revealed that SH2D5 positively regulates the epithelial-mesenchymal transition (EMT) process in lung adenocarcinoma cells. Additionally, we found that regulating the expression of SH2D5 influenced the phosphorylation levels of AKT, and the rescue experiments with AKT pathway activators/inhibitors partially reversed the tumor progression and EMT processes induced by SH2D5. In summary, our study demonstrated that SH2D5 promotes the migration and EMT process of LUAD cells through the AKT signaling pathway, suggesting that SH2D5 may serve as a crucial potential target for the treatment of metastatic LUAD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biology, College of Chemistry & Life Science, Beijing University of Technology, Chaoyang, Beijing, China.
- NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, China CDC, Changping, Beijing, China.
ORCID-Profile: Licheng Du
Zitieren
APA
Du, L., Ren, W., Liu, L., Zhu, H., Xu, K., & Zhou, Y. (2024). SH2D5 promotes lung adenocarcinoma cell metastasis and triggers EMT via activating AKT signaling pathway. PLOS ONE. https://doi.org/10.1371/journal.pone.0316432
Vancouver
Du L, Ren W, Liu L, Zhu H, Xu K, Zhou Y. SH2D5 promotes lung adenocarcinoma cell metastasis and triggers EMT via activating AKT signaling pathway. PLOS ONE. 2024. doi:10.1371/journal.pone.0316432
BibTeX
@article{Du2024,
author = {Du, Licheng and Ren, Wenjia and Liu, Linjun and Zhu, Haojia and Xu, Ke and Zhou, Yubai},
title = {SH2D5 promotes lung adenocarcinoma cell metastasis and triggers EMT via activating AKT signaling pathway},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0316432}
}
EUVIMED